Pfizer (PFE) on Tuesday announced a successful late-stage trial outcome for its multiple myeloma therapy, Elrexfio ...

Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can potentially support treatment across a broad range of settings, ...

Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma ...

The introduction of thalidomide and its derivatives—lenalidomide, followed by pomalidomide—has improved the therapeutic arsenal for multiple myeloma for more than two decades. These immunomodulators ...

Nearly half of patients with multiple myeloma experience pathological fractures, according to a retrospective analysis of 692 ...

Black Americans are more likely to develop multiple myeloma and are often diagnosed at a younger age. The reasons are not fully understood but may involve biological and genetic factors. MGUS, a ...

Metastatic multiple myeloma is a form of cancer of the bone marrow that has spread to other parts of the body. Common sites of metastasis include the skin, muscles, and lymph nodes. Multiple myeloma ...

While it's not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. "Multiple myeloma is a cancer ...

Optimize trial ROI by identifying cost efficient locations, enrollment trends, success rates and key opportunities to sharpen investment strategies and gain a competitive edge.Dublin, Oct. (GLOBE ...

Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal plasma cells accumulate, they crowd out healthy cells and cause symptoms ...

After unexplained arm pain revealed that she had multiple myeloma, Valerie McWilliams found specialized treatment and support at Levine Cancer. In January 2023, Valerie McWilliams began having pain in ...

A new study identifies UBA1 as a primary candidate biomarker for multiple myeloma by integrating ubiquitination and ...